Alora Pharmaceuticals Acquires Osmotica's Legacy U.S. Business

Bora Pharmaceuticals Acquires Upsher-Smith Laboratories

August 5, 2025

Pharmaceuticals

Bora Pharmaceuticals completed a 2024 acquisition of Upsher-Smith Laboratories for $210 million and is expanding the Maple Grove, Minnesota manufacturing site with a multi-year buildout. The investment includes installation of a Gerteis Macro-Pactor (operational Q3 2025) and development of 100,000 square feet of shell space to boost oral solid dose (OSD) contract development and manufacturing capabilities.

Alora Pharmaceuticals Subsidiary Sovereign Acquires Monarch PCM Manufacturing Assets

January 4, 2022

Pharmaceuticals

Alora Pharmaceuticals' wholly owned subsidiary, Sovereign Pharmaceuticals, acquired substantially all manufacturing capabilities of Monarch PCM, LLC in Fort Worth, Texas through bankruptcy proceedings, closing on January 4, 2022. The deal adds 60,000 sq. ft. of manufacturing space and approximately 48 employees, expanding Sovereign's solid, semi-solid and liquid pharmaceutical manufacturing capacity.

Nutra-Med Acquires Legacy Pharma Solutions

October 22, 2024

Manufacturing

Nutra-Med, a portfolio company of GenNx360 Capital Partners, has acquired Legacy Pharma Solutions, a St. Louis-based provider of oral solid dose contract packaging. The acquisition adds high-speed bottling and blistering capabilities to Nutra-Med, expanding its contract packaging capacity for pharmaceutical, OTC and medical device customers.

Alcon Acquires Aerie Pharmaceuticals

August 22, 2022

Pharmaceuticals

Swiss eye-care leader Alcon has acquired Aerie Pharmaceuticals, a Durham, North Carolina-based ophthalmic pharmaceutical company, adding commercial products Rocklatan and Rhopressa as well as a clinical-stage pipeline including AR-15512. The acquisition strengthens Alcon's ophthalmic pharmaceutical capabilities and R&D expertise and is intended to expand distribution and accelerate development of Aerie's portfolio.

Essential Pharma Acquires Yorkdale Pharma from Rosemont; Sells Oral Liquid Portfolio to Rosemont and Buys Two Product Rights from Novartis

December 21, 2021

Pharmaceuticals

Gyrus Capital‑backed Essential Pharma completed a refinancing and executed a series of portfolio transactions in December 2021. Essential Pharma acquired Yorkdale Pharma Limited from Rosemont Pharmaceuticals, divested its 14‑product oral liquid portfolio (Essential Pharma Liquids Limited) to Rosemont, and also acquired worldwide (ex‑US, ex‑India) rights to two products from Novartis to expand its global specialty pharmaceutical portfolio.

Sunshine Biopharma Inc. Acquires Nora Pharma Inc.

October 20, 2022

Pharmaceuticals

Sunshine Biopharma Inc. has completed the acquisition of all outstanding shares of Nora Pharma Inc., making Nora Pharma a wholly owned subsidiary. The deal (C$30.0 million) expands Sunshine’s business into generic prescription drugs, over‑the‑counter products and biosimilars and adds approximately $10.7 million in revenue and 36 employees based in the Greater Montreal area.